Business Wire

New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery

Del

Boehringer Ingelheim announced results from two sub-analyses of the phase III RE-VERSE AD™ study.1,2 The sub-analyses evaluated the safety and efficacy of idarucizumab (marketed as Praxbind®) in reversing the anticoagulant effect of dabigatran etexilate (marketed as Pradaxa®) in patients in diverse emergency situations. These include those with acute bleeding or requiring an urgent surgery or procedure, such as an orthopedic, vascular or abdominal procedure. The analyses were presented at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California, USA. They provide further insights on the use of idarucizumab in patients with gastrointestinal (GI) bleeding and in those with a need for urgent surgery or intervention.

“The RE-VERSE AD study has demonstrated that idarucizumab can reverse the anticoagulant effect of dabigatran within minutes, allowing physicians to quickly initiate emergency interventions for patients who need urgent surgery or are experiencing uncontrollable bleeding,” said Charles Pollack, M.D., lead investigator of RE-VERSE AD, Professor of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA. “These new analyses further reinforce the potential for idarucizumab to enhance care for people living with atrial fibrillation.”

One of the sub-analyses focused on patients with GI bleeding,2 the most common type of bleeding event among patients who were enrolled in the study due to acute bleeding. Of the 137 patients enrolled with a GI bleed, complete reversal of the anticoagulant effect of dabigatran was observed in more than 95 percent of patients. The median time to cessation of bleeding post-idarucizumab administration was less than three hours when the location of the GI bleed was known and 6.4 hours when the location was unknown.

Mortality and thromboembolic event rates for patients with a GI bleed were consistent with the overall findings of RE-VERSE AD™. In the sub-analysis, as presented in the abstracts, at 90 days, there were low thromboembolic event rates of 5.1 percent in patients with a GI bleed, compared to 6.3 percent in non-GI bleed patients. Mortality in the first five days following administration was 6 percent in patients with a GI bleed, compared to 9 percent in non-GI bleed patients. At 90 days, mortality rates were 16 percent and 23 percent, respectively.2

Also presented at AHA were updated results assessing periprocedural bleeding in patients requiring an urgent procedure, such as an emergency surgery.1 Idarucizumab rapidly and completely reversed the anticoagulant effect of dabigatran in approximately 98 percent of patients based on diluted thrombin time (dTT). The median time between administration of idarucizumab and start of surgery was 1.7 hours for patients requiring abdominal procedures, 1.9 hours for orthopaedic procedures, 1.4 hours for vascular procedures, 1.3 hours for drainage procedures and 1.2 hours for catheter procedures. Among these patients, periprocedural bleeding was assessed as normal (if anticoagulation were absent) in more than 92 percent of patients, across all surgery types. Among patients needing emergency surgery, none were assessed as experiencing periprocedural bleeding that was severely abnormal (severe refractory hemorrhage). RE-VERSE AD™ is the only study to investigate anticoagulation reversal among patients requiring surgery.

“The RE-VERSE AD sub-analyses presented at the AHA Scientific Sessions provide insights in two highly relevant areas for patients and physicians,” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Accidents can happen in life, also to patients taking an anticoagulant. Knowing that a fast-acting reversal agent is available is very reassuring to patients and their treating physicians. That is why we continue our efforts to expand the global availability of idarucizumab, the reversal agent for dabigatran.”

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/RE-VERSE-AD-sub-analyses-data-presented-at-AHA-2017

For more information, please visit:  www.boehringer-ingelheim.com

Further Media Channels
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer

Contact information

Boehringer Ingelheim GmbH
Corporate Communications
Media + PR
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail:  press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Mavenir and ADVA Ensemble Partner to Deliver Enterprise LTE Solutions to Managed Service Providers and Enterprises21.2.2018 12:00Pressemelding

Mavenir, focused on transforming mobile network economics for Communications Service Providers, and Ensemble, a Division of ADVA Optical Networking, the leader in Edge NFV solutions, have partnered to provide a complete end-to-end solution for Enterprise LTE. The Enterprise LTE Solution empowers mobile network operators with a revenue-generating solution offering for businesses looking to replace outdated and expensive hardware-based wireless networks. Enterprise solutions require low cost white box architectures that are zero touch from an install perspective. To add complete LTE wireless connectivity to that solution allows the enterprise to install their own partial or complete LTE enterprise wireless that is capable of supporting CBRS and multicarrier solutions. The total global revenue for the private LTE addressable market in industrial and commercial IoT will reach $118.5 billion in 20231. Leveraging NFV as a platform for new and innovative applications, Ensemble and Mavenir hav

The Russian Export Center Will Be Presenting Innovative Russian Solutions at the Mobile World Congress in Barcelona for the First Time21.2.2018 11:21Pressemelding

The Russian Export Center will be introducing home-grown, Russian technology at the 2018 Mobile World Congress (MWC) in Barcelona for the first time. Seventeen Russian companies will showcase their unique, powerful and competitive solutions to a world audience from February 26th to March 1st, from the Russian Booth (Pavilion No. 6, booth 6H20 and 6I11). Information about Russian companies attending is available via the link below: https://drive.google.com/file/d/1pNZ5d8ZOSrC5Ltf_ro_oQVZoo2ylnWqY/view A special business program is organized for the Russian booth, to create opportunities for Russian companies to enter the international market and non-Russian companies to promote their business in Russia. We would like to welcome media and attendees to special events at the Russian Export Center exposition including: - A special session with the leading Russian newspaper "Kommersant", titled "New business opportunities in the digital age" involving Russian and foreign experts (February 26

HSL to Launch a MaaS Interface Open to Everyone on 2 April21.2.2018 11:18Pressemelding

HSL is currently building the world’s first completely open public transport ticketing interface. The interface will allow operators in Finland and abroad to incorporate HSL’s tickets into their array of services. The interface will open for commercial purposes at https://sales-api.hsl.fi on 2 April. HSL is also inviting operators outside the transport sector to develop innovative, new mobility services using the interface. Technical development of the interface will continue and in the future, other tickets may be made available via the interface, in addition to single tickets. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005630/en/ On 19 February, a so called sandbox environment was opened whereby developers can acquaint themselves with the characteristics of the interface’s production environment, and test the compatibility of their own interfaces with the HSL OpenMaas interface. Schedule for HSL’s OpenMaas service

Clientron to Present Its POS Innovation at EuroCIS 201821.2.2018 09:00Pressemelding

Clientron Corp., a global leading provider of POS, thin client, and embedded systems, will display its latest POS solutions for the retail market at the world’s leading retail show, EuroCIS 2018, from February 27 to March 1, 2018 in Dusseldorf, Germany. At its Booth (Hall 10, Booth E73), Clientron will introduce its innovative POS terminals and various built-in POS peripherals available on the market today in order to meet the demands of omnicommerce experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005007/en/ Clientron to present its POS innovation at EuroCIS 2018 At the event, Clientron's displays will include: the innovative PST650 all-in-one POS terminal with a built-in high speed thermal printer and a small, lightweight form factor for counter space savings; the most affordable POS terminal, PT2000, in a fanless design with long life span support to both entry and mainstream POS market segments; and the ne

GSMA: Multiple Mobile Operators Launch Live Commercial Low Power Wide Area Networks in Licensed Spectrum Worldwide21.2.2018 09:00Pressemelding

The GSMA today announced that momentum behind Mobile IoT, or licensed Low Power Wide Area (LPWA), networks continues to grow on a global basis. To date, 23 mobile operators have commercially launched 41 Mobile IoT networks worldwide across both NB-IoT1 and LTE-M2. This growth is supported by 34 IoT Labs and an expanding community of over 800 organisations in the GSMA’s Mobile IoT Innovators Community. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections. “2018 is the year that Mobile IoT networks will scale. We have seen huge growth in the availability of commercial networks in licensed spectrum and anticipate seeing many more launches this year. This is underpinned by an expanding community of organisations developing innovative new solutions and a number of IoT Labs helping companies to test out new products and services,” said Alex Sinclair, Chief Technology Officer, GSMA. “Mobile IoT ne

Fake Medicines Continue to Threaten Consumers – EU Member States have an Obligation to Act21.2.2018 08:12Pressemelding

According to The Alliance for Safe Online Pharmacy in the EU (ASOP EU), the illegal manufacturing and distribution of fake medicines is an enormous and growing public health risk with an untold cost to lives. "Vast profits are made by organized criminal gangs who often use the proceeds to support other criminal activities. The Internet provides the ideal channel to buy illegally distributed fake medicines. Price, convenience and secrecy have driven consumer demand, creating the perfect environment for over 35,000 illegally operating websites." Under article 85d of the Falsified Medicines Directive, each EU Member State is obliged to raise awareness about the risks of buying medicines online. To better understand how countries are meeting these obligations to educate and protect consumers, the European Union’s Alliance for Safe Online Pharmacy (ASOP EU) and the European Alliance for Access to Safe Medicines (EAASM), has convened a series of discussions with many Member States. Based on